Hostname: page-component-8448b6f56d-m8qmq Total loading time: 0 Render date: 2024-04-25T01:31:34.025Z Has data issue: false hasContentIssue false

P-1242 - Schizophrenia Through the Carers’ Eyes: Results of a European Survey

Published online by Cambridge University Press:  15 April 2020

A. Svettini
Affiliation:
EUFAMI, Leuven, Belgium
B. Johnson
Affiliation:
EUFAMI, Leuven, Belgium
C. Magro
Affiliation:
EUFAMI, Leuven, Belgium
J. Saunders
Affiliation:
EUFAMI, Leuven, Belgium
K. Jones
Affiliation:
EUFAMI, Leuven, Belgium
S. Silk
Affiliation:
Janssen EMEA, Johnson & Johnson, High Wycombe, UK
L. Hargarter
Affiliation:
Medical & Scientific Affairs, Janssen EMEA, Johnson & Johnson, Neuss, Germany
A. Schreiner
Affiliation:
Medical & Scientific Affairs, Janssen EMEA, Johnson & Johnson, Neuss, Germany

Abstract

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.
Introduction

Schizophrenia is a serious mental illness that carries a significant burden for families providing care.

Objectives

The ADHES carers' survey canvassed opinions of families/friends of patients with schizophrenia across Europe.

Aim

To ascertain carer attitudes towards schizophrenia, its treatment and treatment adherence.

Methods

The survey was conducted from January-April 2011 in 16 European countries, comprising 10 questions relating to the respondents' understanding of schizophrenia, attitudes towards schizophrenia treatments, and perception of the family's/friend's role in supporting patients with schizophrenia.

Results

Results were obtained from 138 respondents. 76% of carers recognized the importance of medication to help patients get better, improve their quality of life (77%) and relationships (74%). 67% of carers responded that they believed schizophrenia treatment damages patients' general health. Two-thirds of the carers reported that treatment adherence was a burden for the patient and over a third of carers indicated that it was a daily struggle to get patients to take their medication. 50% of carers considered the benefits offered by long-acting injectable antipsychotics as very/quite important and thus, could provide a valuable tool in improving treatment adherence. 92% of carers agreed on the importance of family support to boost treatment adherence with education/information deemed important for families and patients alike.

Conclusion

Carers recognize the issues they face in caring for patients with schizophrenia and their role in improving partial/non-adherence to medication, especially to avoid suboptimal treatment outcomes. The important role of family carers should be considered by healthcare professionals when treating patients with schizophrenia.

Type
Abstract
Copyright
Copyright © European Psychiatric Association 2012
Submit a response

Comments

No Comments have been published for this article.